» Articles » PMID: 30254166

Siglec-7 Engagement by GBS β-protein Suppresses Pyroptotic Cell Death of Natural Killer Cells

Overview
Specialty Science
Date 2018 Sep 27
PMID 30254166
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) cells are innate immune lymphocytes that recognize and destroy abnormal host cells, such as tumor cells or those infected by viral pathogens. To safely accomplish these functions, NK cells display activating receptors that detect stress molecules or viral ligands displayed at the cell surface, balanced by inhibitory receptors that bind to self-molecules. To date, such activating and inhibitory receptors on NK cells are not known to recognize bacterial determinants. Moreover, NK cell responses to direct interactions with extracellular bacteria are poorly explored. In this study, we observed the human neonatal pathogen group B (GBS) can directly engage human NK cells. The interaction was mediated through the B6N segment of streptococcal β-protein, binding to the inhibitory receptor Siglec-7 via its amino-terminal V-set domain. Unlike classical Siglec binding, the interaction is also independent of its sialic acid recognition property. In contrast to WT GBS, mutants lacking β-protein induced efficient pyroptosis of NK cells through the NLRP3 inflammasome, with production and secretion of the proinflammatory cytokine IL-1β and dissemination of the cytotoxic molecule granzyme B. We postulate that GBS evolved β-protein engagement of inhibitory human Siglec-7 to suppress the pyroptotic response of NK cells and thereby block recruitment of a broader innate immune response, i.e., by "silencing the sentinel."

Citing Articles

subsp. RadD binds Siglec-7 and inhibits NK cell-mediated cancer cell killing.

Galaski J, Rishiq A, Liu M, Bsoul R, Bergson A, Lux R iScience. 2024; 27(6):110157.

PMID: 38952680 PMC: 11215305. DOI: 10.1016/j.isci.2024.110157.


Gestational diabetes augments group B Streptococcus infection by disrupting maternal immunity and the vaginal microbiota.

Mercado-Evans V, Mejia M, Zulk J, Ottinger S, Hameed Z, Serchejian C Nat Commun. 2024; 15(1):1035.

PMID: 38310089 PMC: 10838280. DOI: 10.1038/s41467-024-45336-6.


The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.

Feng H, Feng J, Han X, Ying Y, Lou W, Liu L Cancers (Basel). 2024; 16(2).

PMID: 38254780 PMC: 10813689. DOI: 10.3390/cancers16020289.


Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers.

Bordoloi D, Kulkarni A, Adeniji O, Pampena M, Bhojnagarwala P, Zhao S Sci Adv. 2023; 9(44):eadh4379.

PMID: 37910620 PMC: 10619929. DOI: 10.1126/sciadv.adh4379.


Canonical Inflammasomes.

Leal V, Pontillo A Methods Mol Biol. 2023; 2696:1-27.

PMID: 37578712 DOI: 10.1007/978-1-0716-3350-2_1.


References
1.
Mohammadi N, Midiri A, Mancuso G, Patane F, Venza M, Venza I . Neutrophils Directly Recognize Group B Streptococci and Contribute to Interleukin-1β Production during Infection. PLoS One. 2016; 11(8):e0160249. PMC: 4980021. DOI: 10.1371/journal.pone.0160249. View

2.
Angata T, Varki A . Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology. 2000; 10(4):431-8. DOI: 10.1093/glycob/10.4.431. View

3.
Bergsbaken T, Cookson B . Macrophage activation redirects yersinia-infected host cell death from apoptosis to caspase-1-dependent pyroptosis. PLoS Pathog. 2007; 3(11):e161. PMC: 2048529. DOI: 10.1371/journal.ppat.0030161. View

4.
Avril T, Wagner E, Willison H, Crocker P . Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect Immun. 2006; 74(7):4133-41. PMC: 1489752. DOI: 10.1128/IAI.02094-05. View

5.
Michaels J, Garfield S, Hung J, CARDELL Jr R . Labeling of hepatic glycogen after short- and long-term stimulation of glycogen synthesis in rats injected with 3H-galactose. Am J Anat. 1990; 188(4):419-28. DOI: 10.1002/aja.1001880410. View